Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Glofitamab and Obinutuzumab for First-line Treatment of Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596 is registered in ClinicalTrials.gov with Reid Merryman, MD as lead sponsor.

NCT NCT05783596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05783596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Glofitamab and Obinutuzumab for First-line Treatment of Follicular Lymphoma and Marginal Zone Lymphoma
Lead sponsor
Reid Merryman, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 18, 2023
Completion date
August 31, 2029
Enrollment
47 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, indolent non-hodgkin lymphoma, marginal zone lymphoma